Cargando…

Dopamine in Autism Spectrum Disorders—Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment

Autism spectrum disorders (ASD) are a group of disorders characterized by impairment in social communication and repetitive and stereotyped behaviors. ASD etiology is very complex, including the effect of both genetic and environmental factors. So far, no specific treatment for the core symptoms of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandic-Maravic, Vanja, Grujicic, Roberto, Milutinovic, Luka, Munjiza-Jovanovic, Ana, Pejovic-Milovancevic, Milica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850940/
https://www.ncbi.nlm.nih.gov/pubmed/35185637
http://dx.doi.org/10.3389/fpsyt.2021.787097
_version_ 1784652716038946816
author Mandic-Maravic, Vanja
Grujicic, Roberto
Milutinovic, Luka
Munjiza-Jovanovic, Ana
Pejovic-Milovancevic, Milica
author_facet Mandic-Maravic, Vanja
Grujicic, Roberto
Milutinovic, Luka
Munjiza-Jovanovic, Ana
Pejovic-Milovancevic, Milica
author_sort Mandic-Maravic, Vanja
collection PubMed
description Autism spectrum disorders (ASD) are a group of disorders characterized by impairment in social communication and repetitive and stereotyped behaviors. ASD etiology is very complex, including the effect of both genetic and environmental factors. So far, no specific treatment for the core symptoms of ASD has been developed, although attempts have been made for the treatment of repetitive behavior. The pharmacological treatment is aimed at treating non-specific symptoms such as irritability and aggression. Recent studies pointed out to the possible role of altered dopamine signaling in mesocorticolimbic and nigrostriatal circuits in ASD. In addition, several research pointed out to the association of dopamine receptors polymorphism and ASD, specifically repetitive and stereotyped behavior. In this paper, we will provide a review of the studies regarding dopamine signaling in ASD, existing data on the effects of D2/D3 partial agonists in ASD, possible implications regarding their individual receptor profiles, and future perspectives of their possible use in ASD treatment.
format Online
Article
Text
id pubmed-8850940
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88509402022-02-18 Dopamine in Autism Spectrum Disorders—Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment Mandic-Maravic, Vanja Grujicic, Roberto Milutinovic, Luka Munjiza-Jovanovic, Ana Pejovic-Milovancevic, Milica Front Psychiatry Psychiatry Autism spectrum disorders (ASD) are a group of disorders characterized by impairment in social communication and repetitive and stereotyped behaviors. ASD etiology is very complex, including the effect of both genetic and environmental factors. So far, no specific treatment for the core symptoms of ASD has been developed, although attempts have been made for the treatment of repetitive behavior. The pharmacological treatment is aimed at treating non-specific symptoms such as irritability and aggression. Recent studies pointed out to the possible role of altered dopamine signaling in mesocorticolimbic and nigrostriatal circuits in ASD. In addition, several research pointed out to the association of dopamine receptors polymorphism and ASD, specifically repetitive and stereotyped behavior. In this paper, we will provide a review of the studies regarding dopamine signaling in ASD, existing data on the effects of D2/D3 partial agonists in ASD, possible implications regarding their individual receptor profiles, and future perspectives of their possible use in ASD treatment. Frontiers Media S.A. 2022-02-03 /pmc/articles/PMC8850940/ /pubmed/35185637 http://dx.doi.org/10.3389/fpsyt.2021.787097 Text en Copyright © 2022 Mandic-Maravic, Grujicic, Milutinovic, Munjiza-Jovanovic and Pejovic-Milovancevic. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychiatry
Mandic-Maravic, Vanja
Grujicic, Roberto
Milutinovic, Luka
Munjiza-Jovanovic, Ana
Pejovic-Milovancevic, Milica
Dopamine in Autism Spectrum Disorders—Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment
title Dopamine in Autism Spectrum Disorders—Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment
title_full Dopamine in Autism Spectrum Disorders—Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment
title_fullStr Dopamine in Autism Spectrum Disorders—Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment
title_full_unstemmed Dopamine in Autism Spectrum Disorders—Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment
title_short Dopamine in Autism Spectrum Disorders—Focus on D2/D3 Partial Agonists and Their Possible Use in Treatment
title_sort dopamine in autism spectrum disorders—focus on d2/d3 partial agonists and their possible use in treatment
topic Psychiatry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8850940/
https://www.ncbi.nlm.nih.gov/pubmed/35185637
http://dx.doi.org/10.3389/fpsyt.2021.787097
work_keys_str_mv AT mandicmaravicvanja dopamineinautismspectrumdisordersfocusond2d3partialagonistsandtheirpossibleuseintreatment
AT grujicicroberto dopamineinautismspectrumdisordersfocusond2d3partialagonistsandtheirpossibleuseintreatment
AT milutinovicluka dopamineinautismspectrumdisordersfocusond2d3partialagonistsandtheirpossibleuseintreatment
AT munjizajovanovicana dopamineinautismspectrumdisordersfocusond2d3partialagonistsandtheirpossibleuseintreatment
AT pejovicmilovancevicmilica dopamineinautismspectrumdisordersfocusond2d3partialagonistsandtheirpossibleuseintreatment